

## Jill Carlton – Publications

### Book Chapters – in Print

1. (P) **Carlton J**, Czoski-Murray C. The value of screening for amblyopia revisited. *Essentials in Ophthalmology*. Springer, 2010: 95-111

### Refereed Journals - in Print

#### 2013

2. (P) **Carlton J**. Identifying potential themes for the Child Amblyopia Treatment Questionnaire. *Optom Vis Sci* 2013; Epub ahead of print
3. (P) **Carlton J**. The Child Amblyopia Treatment Questionnaire (CAT-QoL): A new paediatric disease-specific measure of quality of life for amblyopia. *PRO Newsletter* 2013; 49:11-12
4. (P) **Carlton J**, Arblaster GE, Hughes LA. The BIOJ: A comparative review. *Br Ir Orthopt J*. In press.
5. (P) **Carlton J**, Arblaster GE, Hughes LA. The BIOJ: Evolution or revolution? *Br Ir Orthopt J*. In press.

#### 2012

6. (J) Browne C, Brazier J, **Carlton J**, Alavi Y, Jofre-Bonet M. Estimating quality-adjusted life years from patient-reported visual functioning. *Eye* 2012; 26(12): 1295-301

#### 2011

7. (P) **Carlton J**. General health-related quality of life in preschool children with strabismus or amblyopia. *Evidence-Based Ophthalmology*. 2011; 12(4): 212-213
8. (P) **Carlton J**, Kaltenthaler E. Health related quality of life measures (HRQoL) in patients with amblyopia and strabismus: a systematic review. *Br J Ophthalmol* 2011; 95(3): 325-330
9. (P) **Carlton J**. Clinicians' perspectives of health related quality of life (HRQoL) implications of amblyopia: a qualitative study. *Br Ir Orthopt J*. 2011; 8: 18-23
10. (P) **Carlton J**, Auld R. What is vision screening? And more importantly what is it not? *Br Ir Orthopt J*. 2011; 8: 67-69
11. (P) **Carlton J**, Smith K. Screening for amblyopia. *J Pediatr Ophthalmol Strabismus*. 2011;48(6): 381

#### 2010

12. (P) **Carlton J**, Kaltenthaler E. Amblyopia and quality of life: a systematic review. *Eye* 2010; 25(4): 403-413
13. (J) Rowen D, **Carlton J**, Brazier JE, Mulhern B, Palfreyman S, Stevens K, Tsuchiya A. FDA on PROMs: Two important points. *Br Med J* 2010; 341: c5454
14. (J) Rowen D, **Carlton J**, Brazier J, Mulhern B, Palfreyman S, Stevens K, Tsuchiya A. Comment on FDA guidance for patient-reported outcome measures. *Br Med J* 2010; 340: c2921

#### 2009

15. **(J)** Karnon J, **Carlton J**, Czoski-Murray C, Smith K. Informing disinvestment through cost-effectiveness modelling: Is lack of data a surmountable barrier? *Appl Health Econ Health Policy*. 2009; 7(1): 1-9
16. **(P)** **Carlton J**, Czoski-Murray C. Screening for amblyopia and strabismus in children aged 4-5 years: where do we go from here? *Br Ir Orthopt J*. 2009; 6: 15-21
17. **(J)** Czoski-Murray C, **Carlton J**, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. *Value Health*. 2009; 12(5): 793-799

#### **2008**

18. **14. (P)** **Carlton J**, Karnon J, Czoski-Murray C, Smith KJ, Marr J. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. *Health Technol Assess* 2008; 12(25): iii, xi-194

#### **2007**

19. **15. (J)** Bansback N, Czoski-Murray C, **Carlton J**, Lewis G, Hughes L, Espallargues M, Brand C, Brazier J. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. *Qual Life Res*. 2007; 16(3): 533-543

#### **2006**

20. **16. (J)** Brazier JE, Czoski-Murray C, **Carlton J**. The role of generic measures of health status in ARMD . *Br Med J* 2006; 333: 869-870

#### **2005**

21. **17. (J)** Espallargues M, Czoski-Murray C, Bansback N, **Carlton J**, Lewis G, Hughes L, Brand C, Brazier J. The impact of age related macular degeneration on health state utility values. *Invest Ophthalmol Vis Sci*. 2005; 46(11): 4016-4023

## Discussion Papers and Online Materials

22. **(P) Carlton J.** Development of the Child Amblyopia Treatment Questionnaire (CAT-QoL): a disease-specific health related quality of life measure (HRQoL) for amblyopia. (2011). Health Economics and Decision Science Discussion Paper 11/14. Available from: <http://www.shef.ac.uk/scharr/sections/heds/discussion>
23. **(P) Carlton J.** Clinicians' perspectives of health related quality of life (HRQoL) implications of amblyopia: a qualitative study. (2010) Health Economics and Decision Science Discussion Paper 10/14. Available from: <http://www.shef.ac.uk/scharr/sections/heds/discussion>
24. **(P) Carlton J, Kaltenthaler E.** Amblyopia and quality of life: a systematic review. (2010) Health Economics and Decision Science Discussion Paper 10/05. Available from: <http://www.shef.ac.uk/scharr/sections/heds/discussion>
25. **(J) Czoski-Murray C, Carlton J, Brazier J, Kang HK, Young TA, Papo N.** Valuing condition specific health states using simulation contact lenses. (2007) Health Economics and Decision Science Discussion Paper 07/05. Available from; <http://www.shef.ac.uk/scharr/sections/heds/discussion>
26. **(P) Carlton J.** Invited Contributor to the NHS Evidence-eyes and vision – Update on Amblyopia. 2010. [www.rcophth.ac.uk/core/core\\_picker/download.asp?id=939](http://www.rcophth.ac.uk/core/core_picker/download.asp?id=939)

## Conference Presentations (underline denotes speaker)

27. (P) Carlton J. Measuring health: An overview of PROM development and application. British and Irish Orthoptic Society Clinical Meeting, Northern Branch. Liverpool, 28<sup>th</sup> November 2012. (*Invited speaker*).
28. (P) Carlton J. QALYs: How these are used in decisions on health service provision. British and Irish Orthoptic Society Special Interest Group Meeting. Leeds, 15<sup>th</sup> November 2012. (*Invited speaker*).
29. (P) Carlton J. Measuring health: An overview of PROM development and application. British and Irish Orthoptic Society Clinical Meeting, Welsh Branch. Wrexham, 15<sup>th</sup> October 2012. (*Invited speaker*).
30. (P) Carlton J. Measuring health: An overview of PROM development and application. British and Irish Orthoptic Society Clinical Meeting, Midland Branch. Walsall, 27<sup>th</sup> September 2012. (*Invited speaker*).
31. (P) Carlton J. Development of a paediatric disease-specific health-related quality of life measure for amblyopia: the Child Amblyopia Treatment Quality of Life Questionnaire (CAT-QoL). XII<sup>th</sup> International Orthoptic Scientific Congress. Toronto, Canada, 26<sup>th</sup>-29<sup>th</sup> June 2012.
32. (P) Carlton J. Questionnaire options for Vision-related quality of life measures. UKISCRS XXXV Congress. Southport, 13<sup>th</sup>-14<sup>th</sup> October 2011. (*Invited speaker*).
33. (P) Carlton J. The development of the CAT-QoL (Children's Amblyopia Treatment Quality of Life Questionnaire). British Isles Paediatric Ophthalmology and Strabismus Association (BIPOSA). 12<sup>th</sup>-14<sup>th</sup> October 2011.
34. (P) Carlton J. Development of a health related quality of life instrument for amblyopia. British and Irish Orthoptic Society Scientific Conference. 8<sup>th</sup>-9<sup>th</sup> September 2011. (*Invited speaker*).
35. (P) Carlton J. Screening for amblyopia and strabismus – should we bother? British and Irish Orthoptic Society Vision Screening Special Interest Group. Birmingham, 24<sup>th</sup> September 2010. (*Invited speaker*).
36. (P) Carlton J. Cash, Kids and Questions. Ophthalmology Directorate Research Meeting, Sheffield Teaching Hospitals NHS Foundation Trust. Sheffield, 8<sup>th</sup> September 2010. (*Invited speaker*).
37. (P) Carlton J. Impact of amblyopia on quality of life. World Ophthalmological Congress 2010. Berlin, 5<sup>th</sup>-9<sup>th</sup> June 2010. (*Invited speaker*).
38. (P) Carlton J. Cost-effectiveness of screening programmes for amblyopia. World Ophthalmological Congress 2010. Berlin, 5<sup>th</sup>-9<sup>th</sup> June 2010. (*Invited speaker*).
39. (J) Brazier J, Poku E, Carlton J. Does vision matter: a systematic review of the relationship between visual acuity and utilities. Royal College of Ophthalmologists Annual Congress, Liverpool 25-27<sup>th</sup> May 2010.
40. (P) Carlton J. Challenges encountered in developing PROMs: The experience so far in the creation of a PROM for amblyopia in the paediatric population. Part of Symposium: Going to the PROM? Are patient reported outcome measures (PROMs) a useful tool to measure the impact of nursing interventions? International Nursing Research Conference. Newcastle, 11-13<sup>th</sup> May 2010.

41. **(P)** **Carlton J.** Development of a paediatric disease-specific measure of health related quality of life in amblyopia. British Isles Paediatric Ophthalmology and Strabismus Association (BIPOSA). Glasgow, 23<sup>rd</sup>-25<sup>th</sup> September 2009.
42. **(P)** **Carlton J.** Quality of life issues in amblyopia. British and Irish Orthoptic Society Professional Development Meetings. Leeds, 9<sup>th</sup> September 2009. (*Invited speaker*).
43. **(P)** **Carlton J.** Quality of life issues in amblyopia. British and Irish Orthoptic Society Professional Development Meetings. Bristol, 16<sup>th</sup> September 2009. (*Invited speaker*).
44. **(P)** **Carlton J.** Quality of life issues in amblyopia. Rotterdam Amblyopia Meeting, University Medical Centre Rotterdam, 12<sup>th</sup> February 2009. (*Invited speaker*).
45. **(P)** **Carlton J.** Phippen G, Hughes L, Czoski-Murray C, Bansback N, Espallargues M, Brand C, Brazier J. A survey of quality of life in patients with age related macular degeneration. Transactions of Xth International Orthoptic Congress, Melbourne, Australia, 14<sup>th</sup>-17<sup>th</sup> November 2004.
46. **(P)** **Carlton J.** Lateral gaze incomitance in distance exotropia: should the neutralising prism be placed over the abducting or adducting eye? British Isles Strabismological Association (BISA), 7<sup>th</sup> October 2004.

## Conference Posters

47. (P) **Carlton J**, Kaltenthaler E. Health related quality of life measures (HRQoL) in orthoptics. British and Irish Orthoptic Society Scientific Conference. Oxford, 1<sup>st</sup>-2<sup>nd</sup> July 2010.
48. (J) Carolyn J. Czoski Murray, **Jill Carlton**, John E. Brazier, Tracey A. Young, Hyong Kwon Kang, Natalie Papo. (2007). Visual impairment states: valuation using simulation lenses. 14<sup>th</sup> Annual Conference for the International Society for Quality of Life Research "Health Related QOL Research: From Measurement to Understanding. Toronto, Canada, 10<sup>th</sup>-13<sup>th</sup> October 2007. Meeting abstracts [[www.isoqol.org/2007mtgabstracts.pdf](http://www.isoqol.org/2007mtgabstracts.pdf)]. *Quality of Life Research supplement*, A-86, Abstract #1830
49. (J) Czoski- Murray C, **Carlton J**, Young T, Brazier J, Papo N, Kwon Kang H. Health state valuation for ARMD visual impairment states using simulation lenses. 6th iHEA World Congress on Health Economics. Copenhagen, Denmark July 2007.
50. (J) Brazier J, Bansback N, Espallargues M, Czoski-Murray C, Phippen G, **Carlton J**. Are generic preference-based measures truly generic? The case of visual impairment. 5<sup>th</sup> iHEA World Congress on Health Economics. Barcelona, Spain July 2005.
51. (J) Espallargues M, Brazier J, Czoski-Murray C, Bansback N, Phippen G, **Carlton J**. Health status measurement in Age-Related Macular Disease: new evidence for clinic and economic evaluation. Health Technology Assessment International (HTAi), Krakow, Poland 30th May-2nd June 2004
52. (J) Brazier J, Bansback N, Espallargues M, Czoski-Murray C, Phippen G, **Carlton J**. The relationship between impairment and generic preference based measures, patient valuations and patient life satisfaction in Age Related Macular Degeneration. European Conference on Health Economics, London School of Economics, London 2005.

## Reports

53. (J) Brazier J, Poku E, Cooper K, **Carlton J**. Reviewing the impact of visual acuity on utility values and assessing the appropriateness of the EQ-5D in Diabetic Macular Edema. Review 1. Report to Novartis. April 2010.
54. (J) Brazier J, Poku E, Cooper K, **Carlton J**. Reviewing the impact of visual acuity on utility values and assessing the appropriateness of the EQ-5D in Diabetic Macular Edema. Review 2. Report to Novartis. April 2010.
55. (J) Brazier J, Kwon Kang H, **Carlton J**, Czoski-Murray C. General population survey to obtain values for AMD visual impairment states using lenses. Final Report to Novartis. March 2006.